Skip to content

Trial · Interventional

CompletedPhase 2Registry data

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCTNCT05936151 (opens ClinicalTrials.gov in a new tab)Other id18725Other idJ1I-MC-GZBUOther id2023-504583-42-00Other id2023
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
146 participants (actual)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Double masking
Countries
5 countries

United States, Canada, Italy, Spain, United Kingdom

Start
20 Jul 2023
Primary completion
1 Oct 2025
Completion
21 Oct 2025
First posted
7 Jul 2023
Last update posted
25 Nov 2025
Conditions
Overweight or Obesity · CKD · Type 2 Diabetes

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2023202420252026
  1. Ph 2

    A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    NCT05936151

    20 Jul 2023 to 21 Oct 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

Interventions

  • RetatrutideDrug
  • PlaceboDrug

Arms2

  • Experimental

    Retatrutide

    Participants will receive multiple doses of retatrutide subcutaneously (SC)

  • Placebo comparator

    Placebo

    Participants will receive LY3437943

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change from Baseline in Glomerular Filtration Rate (mGFR)

    Time frame · Baseline, Week 24

    Registry description

    The GFR in milliliter/minute per1.73 square meter (mL/min/1.73 m²) using iohexol clearance (mGFR-measured glomerular filtration rate)

Secondary outcomes(17)

  1. Change from Baseline in Urine Albumin-to-Creatinine Ratio (UACR)

    Time frame · Baseline, Week 24

  2. Change from Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa)

    Time frame · Baseline, Week 24

  3. Change from Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR)

    Time frame · Baseline, Week 24

  4. Change from Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit

    Time frame · Baseline, Week 24

  5. Change from Baseline in in Mean Arterial Flow (MAF)

    Time frame · Baseline, Week 24

  6. Change from Baseline in Renal Artery Resistive Index (RARI)

    Time frame · Baseline, Week 24

  7. Change from Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) and End-diastolic Velocity (ESV)

    Time frame · Baseline, Week 24

  8. Change from Baseline in Global Renal Perfusion (MRI)

    Time frame · Baseline, Week 24

  9. Change from Baseline in Total Renal Parenchyma Volume (MRI)

    Time frame · Baseline, Week 24

  10. Change from Baseline in Renal Cortex Volume (MRI)

    Time frame · Baseline, Week 24

  11. Change from Baseline in Renal Cortex T1 (ms) (MRI)

    Time frame · Baseline, Week 24

  12. Change from Baseline in Medulla T1 (ms) (MRI)

    Time frame · Baseline, Week 24

  13. Change from Baseline in Renal Cortex R2 (BOLD MRI)

    Time frame · Baseline, Week 24

  14. Change from Baseline in Medulla R2

    Time frame · Baseline, Week 24

  15. Change from Baseline in Body Weight

    Time frame · Baseline, Week 24

  16. Change from Baseline in 24-hr Urinary Albumin Excretion (UAE)

    Time frame · Baseline, Week 24

  17. Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h))

    Time frame · Baseline, Week 24

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

0 studies on this page

Indexing hint: Clinical trial · 2026

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.

Heerspink et al. 2026Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Associationcited by 4

PMID 41160422PMC13218929DOI 10.1093/ndt/gfaf230PUB-41160422

CC BY
Download PDF

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²) * Have either * no T2D with an HbA1c \< 6.5% or * have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening. * Have been diagnosed with chronic kidney disease (CKD). Exclusion Criteria: * Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening. * Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes (T1D) * Have acute or chronic hepatitis * Have a history of malignant disease within 5 years before screening.

PepBank is a research reference. Talk to a doctor before you use any peptide.